June 27 (Reuters) - Morphosys AG:
* Morphosys and xencor sign license and collaboration agreement for clinical
antibody program
* Says agreement for an antibody in phase 1 clinical development
* Says xencor will receive an upfront payment of US$ 13 million
* Says further financial terms were not disclosed
* Says continues to anticipate total internal investment in proprietary
research and development of EUR26-29 million
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Morphosys AG click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Morphosys and xencor sign license and collaboration agreement for clinical
antibody program
* Says agreement for an antibody in phase 1 clinical development
* Says xencor will receive an upfront payment of US$ 13 million
* Says further financial terms were not disclosed
* Says continues to anticipate total internal investment in proprietary
research and development of EUR26-29 million
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Morphosys AG click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.